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Abstract
Background:  Pigment epithelium-derived factor (PEDF) has binding affinity for cell-surface
receptors in retinoblastoma cells and for glycosaminoglycans. We investigated the effects of
glycosaminoglycans on PEDF-receptor interactions.
Results:  125I-PEDF formed complexes with protease-resistant components of medium
conditioned by human retinoblastoma Y-79 cells. Using specific glycosaminoglycan degrading
enzymes in spectrophotometric assays and PEDF-affinity chromatography, we detected heparin and
heparan sulfate-like glycosaminoglycans in the Y-79 conditioned media, which had binding affinity
for PEDF. The Y-79 conditioned media significantly enhanced the binding of 125I-PEDF to Y-79 cell-
surface receptors. However, enzymatic and chemical depletion of sulfated glycosaminoglycans from
the Y-79 cell cultures by heparitinase and chlorate treatments decreased the degree of 125I-PEDF
binding to cell-surface receptors.
Conclusions: These data indicate that retinoblastoma cells secrete heparin/heparan sulfate with
binding affinity for PEDF, which may be important in efficient cell-surface receptor binding.
Background
Glycosaminoglycans (GAGs) are negatively charged
polysaccharides derived from an amino hexose. They are
structural and functional modulators of extracellular ma-
trices that play important roles in CNS development and
repair. They exhibit both stimulatory and inhibitory influ-
ences on neurite outgrowth and survival. Evidence dem-
onstrates the ability of heparin sulfates (HSs) to bind to
growth/trophic factors and selectively regulate such fac-
tors' receptors. [1,2]. They can act as co-receptors of
growth/trophic and survival factors to regulate cell behav-
ior and/or restrict diffusion and create a relatively high lo-
cal concentration of ligand.
Pigment epithelium-derived factor (PEDF) is an extracel-
lular neuronal differentiation and survival factor for cells
derived from the retina and CNS. It induces neuronal dif-
ferentiation in retinoblastoma cells, protects retina neu-
rons (including photoreceptors) from death by apoptosis
and other insults, and has a morphogenetic effect on pho-
toreceptor cells [3–6]. It also has neurotrophic effects on
neurons from the cerebellum, hippocampus and spinal
cord [7–12]. In the intact retina, this factor is identified as
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a secreted protein associated by ionic interactions with the
interphotoreceptor matrix [13,14], where GAGs are the
major polyanionic components.
Biochemically, PEDF is a 50-kDa glycoprotein with struc-
tural homology to members of the serine-protease inhib-
itor (serpin) superfamily [3,15]. However, it has no
inhibitory effects on proteases. Its neurotrophic activities
are independent of its protease inhibition potential but
dependent on its interaction with cell-surface receptors
[9,12,16–18]. PEDF has high binding affinity for cell-sur-
face receptors in human retinoblastoma Y-79 cells (Kd =
2.7 nM), which is mediated by interactions between a re-
gion spanning amino acid positions 78–121 of the PEDF
polypeptide and the extracellular domains of the receptor
protein [18]. Blockage of these interactions inhibits the
PEDF neurotrophic effects. PEDF also has binding affinity
for GAGs, such as, heparin, heparin- and chondroitin-sul-
fates, but this affinity is ~1000-fold lower than for the re-
ceptor (e.g., Kd   4 µM for the heparin-PEDF
interactions) [14,19]. The binding to GAGs is mediated by
ionic interactions between an area clustered with positive-
ly charged lysines of PEDF and the negatively charged
GAGs. In the PEDF spatial structure, the putative GAG
binding domain is distinct from and non-overlapping
with the neurotrophic active region [14,20].
Because PEDF coexists with GAGs in extracellular matrices
and has binding affinity for them, it is of interest to inves-
tigate the role of GAGs on PEDF activity. Given that bind-
ing to cell-surface receptors is the first step in the
biological activity of PEDF, we used human retinoblasto-
ma Y-79 cells and their conditioned media (CM) as sourc-
es of functional PEDF receptors and extracellular matrix
components, respectively, to examine the GAG content in
CM and their effects on PEDF ligand-receptor interac-
tions. The data suggest that heparan sulfate participates in
the formation of a PEDF binding complex with its cell-sur-
face receptor, and constitutes a positive modulator for the
PEDF-receptor interactions.
Results
Complex formation between PEDF and component(s) in 
media conditioned by retinoblastoma cells
To determine whether PEDF interacts with component(s)
in media conditioned by retinoblastoma cells (CM), we
used an ultrafiltration assay. In this assay, soluble PEDF of
50-kDa is filtered through a membrane with an exclusion
limit of MW 100,000, however it is retained upon forma-
tion of a complex larger than this limit [14]. The binding
reactions were with a given 125I-PEDF concentration and
CM. Incubations were at 4°C to minimize enzymatic deg-
radation of proteins and glycosaminglycans during the re-
action. We found that 22% of 125I-PEDF was retained by
the membrane in the presence of concentrated CM, com-
pared to only 4% retention in the presence of defined me-
dium (non-conditioned medium) concentrated in an
identical fashion. Specific retention, termed PEDF bound,
was calculated by subtracting the retention in defined me-
dia from that in CM. Figure 1 shows that PEDF was specif-
ically retained when mixed with soluble conditioned
media and the value for PEDF bound increased propor-
tionally to the concentration factor of the media (Fig. 1A).
Interestingly, protease treatment of the CM did not abol-
ish the binding (Fig. 1B). These observations revealed that
the retained forms in the CM were PEDF complexes ≥ 100-
kDa, and that the majority of these complexes were
formed with soluble CM components other than proteins.
Heparin and HS in the conditioned media with affinity for 
PEDF
GAGs and polyanions in the CM were fractionated by an-
ion-exchange column chromatography followed by
PEDF-affinity column chromatography (Fig. 2). The GAG
content was followed by staining with Toluidine Blue-O
≅
Figure 1
Complex formation between PEDF and compo-
nent(s) in media conditioned by human retinoblast-
oma Y-79 cells. Binding reactions were performed with 
0.75 nM 125I-PEDF and human retinoblastoma Y-79 cell con-
ditioned media (CM) (200 µl) at 4°C for 120 min with gentle 
rotation. Free and bound PEDF was separated by ultrafiltra-
tion through membrane of MWCO = 100 kDa. PEDF bound 
was calculated by subtracting specific 125I-PEDF binding in 
fresh media from that in CM and is given as a ratio of the 
total 125I-PEDF in the reaction. A) Reactions with CM (CM 
1X) and 10-fold concentrated CM (CM 10X). B) Reactions 
with protease-treated CM. CM was concentrated 10-fold 
and dialyzed against 20 mM Tris pH 8, 10% glycerol. Half of 
the dialyzate was incubated without and the other with 0.4 
µg/ml subtilisin at 37°C for 16 h (-Subt. and +Subt., respec-
tively). The protease reaction was terminated by incubation 
at 75°C for 25 min to inactivate the protease. All experimen-
tal points are given as the average of duplicates. Assays were 
performed twice.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/1
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(Fig. 2C,2D,2E). The final fraction (CMPEDF) contained
components with binding affinity for PEDF that stained
with Toluidine Blue-O and migrated as high molecular
weight GAGs.
To determine the type of sulfated GAG in the media, we
designed a spectrophotometric assay using heparinase
and heparitinase, specific degrading enzymes for heparin
and HS, respectively (Fig. 3). The activities of both GAG
lyases reached a plateau by one hour of incubation (Figs.
3A,3C) and the degradation of GAG substrates between
0–30 µg was linear. Both CM and CMPEDF contained sub-
strates for heparinase and heparitinase (Figs. 3B,3D). The
amount of GAGs was determined by comparison of the
amount of ∆4-hexuronate produced with CM samples to
the standard curves with commercial GAGs. The estimated
content of GAGs in CM varied between 12.4–22.7 µg/ml
for heparin and between 9–10 µg/ml for HS-like mole-
cules, among media conditioned by three different batch-
es of Y-79 cells. The estimated GAG content in CMPEDF
ranged 0.2–1.8 µg/µl and 0.1–0.4 µg/µl for heparin and
HS, respectively. Similar assays were followed with chon-
droitinase ABC, but its substrates, ∆Di4S, dermatan and
∆Di6S, in CM were below detection limits. These results
demonstrated that CM and CMPEDF contained heparin-
and HS-like molecules, demonstrating that Y-79 cells pro-
duced GAGs with binding affinity for PEDF.
Media conditioned by retinoblastoma cells enhances the 
125I-PEDF binding to cell-surface receptors
We have demonstrated previously that biologically active
125I-PEDF binds specifically, competitively and with high
affinity to cell-surface receptors of Y-79 cells [18]. Because
the reaction conditions were identical to those used for bi-
ological assays, the binding reactions were performed in
the presence of media conditioned by the cells for 16
hours (CM). We investigated the effect of components of
the CM, a source of extracellular matrix, on the PEDF-re-
ceptor interactions using CM and non-conditioned de-
fined media in radioligand binding assays. Comparison
of reactions in the absence and presence of CM showed
that the specific PEDF-binding to Y-79 cell-surface recep-
tors was 6.8-fold higher with conditioned medium than
with defined medium (Fig. 4). Note that with the binding
method used, the amount of 125I-PEDF retained in CM
without cells is the same to the amount of non-specific
125I-PEDF binding (reactions with cells and in the pres-
ence of 50-fold molar excess of unlabeled PEDF) [18], in-
dicating retention by PEI-treated glass-fiber filters of
PEDF-receptor or GAG-PEDF-receptor complexes rather
than PEDF-GAG. Similar results were obtained when the
cell-bound  125I-PEDF was separated by centrifugation,
rather than filtration through glass-fiber filters, and com-
paring reactions with CM versus those with 1% BSA in
PBS (data not shown). These observations showed that a
component(s) secreted by retinoblastoma cells enhanced
the PEDF-receptor interactions.
Figure 2
DEAE-Sephacel and PEDF-affinity column chroma-
tography of media conditioned by retinoblastoma 
cells. GAGs and polyanions of CM were fractionated by 
anion-exchange column chromatography (CMa). CM (2.5 mg 
protein) was applied to a DEAE-Sephacel column and the 
bound components were eluted with a linear gradient of 0.2–
1 M NaCl. Panel A. Protein profile of the DEAE-Sephacel chro-
matography. Protein (--) and NaCl (-----) concentrations of 
eluted fractions are indicated. The load, unbound material 
(FT), and fractions 7 and 9 were resolved by 4–12% polyacr-
ylamide gel electrophoresis under reducing conditions in two 
duplicate gels. Panels B and C.  SDS-PAGE analysis of the 
DEAE chromatography. Gels stained with Coomassie Brilliant 
Blue (panel B) and with Toluidine Blue-O (panel C) are 
shown. Lane 1, load; lane 2, flow-through; lane 3 fraction #7; 
and lane 4, fraction #9. Panels D and E. PEDF-affinity column 
chromatography. CMa was subjected to PEDF-affinity column 
chromatography. Bound GAGs were eluted with 3 M NaCl 
(CMPEDF). Unbound material is FT and washes W1 and W2., 
A dot-blot stained with Toluidine Blue-O of fractions (as 
indicated) is shown in panel D. A 10–20% polyacrylamide gel 
(SDS-tricine) stained with Toluidine Blue-O is shown in Panel 
E with: lane 1, CMPEDF; lane 2, 5 µg heparin of average MW 
16,000; and lane 3, 5 µg HS. Migration positions of molecu-
lar-weight-standards are indicated to the right. Arrows indi-
cate migration positions of GAGs from CM derived samples.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/1
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Effect of GAG lyases and chlorate on 125I-PEDF binding to 
cell-surface receptors
To deplete the Y-79 cell cultures of HS and heparin-like
GAGs, we used heparitinase and heparinase, respectively.
The cultures were pretreated with each GAG lyase before
using them in radioligand binding assays. The morpholo-
gy and viability of the cells were not affected with the GAG
lyase treatments. Figure 5A shows that specific 125I-PEDF
binding decreased significantly in heparitinase treated
cultures compared to untreated controls, and less drasti-
cally in heparinase treated ones. Hyaluronidase treatment
to deplete the cultures of hyaluronan did not have an ef-
fect on the binding. These results demonstrated that re-
moval of heparin/HS from the cell cultures decreased the
PEDF binding to receptors on Y-79 cells. Chlorate is a
competitive inhibitor of ATP-sulfurylase, and inhibition
of GAG sulfation in cell cultures can be achieved by pre-
treatment of the cultures with 30 mM sodium chlorate
[21]. The effect of undersulfated GAGs on the PEDF bind-
ing to its receptor was examined. Cells pretreated with so-
dium chlorate did not show changes in viability or
morphology; however, the treatment resulted in a de-
crease in the specific 125I-PEDF binding to about 35% rel-
ative to untreated controls (Fig. 5B). Sodium sulfate was
used to recover the loss of GAG sulfation by chlorate in-
creasing the binding to 55% maximal with 10 mM sulfate
additions. The data revealed that inhibition of sulfation of
GAGs reduced the PEDF binding to cell-surface receptors
of Y-79 cells, with about 20% of specific inhibition. Thus,
these observations implied that HS/heparin might play a
functional role in the binding of PEDF to its cell-surface
receptor.
Discussion
It has been proposed that the GAG-binding property of
PEDF provides the molecular basis for its association with
extracellular matrices and may serve to localize PEDF ac-
tivity in the retina and CNS [14,19]. However, the present
results point to direct effects these polysaccharides might
have on the biochemical interactions between PEDF and
PEDF receptors on the surfaces of cells that respond to this
neurotrophic factor. We have shown that the binding of
PEDF to receptors in retinoblastoma cells is enhanced by
the presence of extracellular heparin/HS-like GAGs, which
can be found in the culture medium of retinoblastoma
cells. The fact that the binding of PEDF to cell surfaces de-
creases with heparin/HS depletion, implies that heparin/
HS molecules might act as cofactors for PEDF-receptor in-
teractions. Interactions between PEDF and extracellular
GAGs can also explain the complex formed by PEDF with
CM even after protease treatment of the latter. The PEDF-
heparin/HS complex may somehow facilitate encounters
between PEDF and its receptor, e.g., by inducing a confor-
mational change in PEDF, which might accelerate the lig-
and-receptor interactions. In addition, the receptor may
also form a complex with heparin/HS to facilitate interac-
tions with the ligand.
To our knowledge, this is the first report on the produc-
tion of GAGs by retinoblastoma cells. We found that these
cells produce HS/heparin secreted into the culturing me-
dia. The retina and malignant solid tumors also produce
the sulfated GAGs [1,2,22–26]. Although HSs are mostly
found as proteoglycans associated with the basal lamina
or the plasma membrane, the presence of HSs in the cul-
turing medium might be a result of shedding or release of
their extracellular domains from the cell membranes as
soluble components. Cell-associated HS proteoglycans
can undergo regulated shedding from the membrane into
the soluble extracellular matrix or culturing medium con-
verting the membrane anchored molecules into soluble
effectors [1,2]. In the conditioned media of all the tested
batches of retinoblastoma cells, we detected heparin and
Figure 3
Spectrophotometric assays for heparin and HS-like 
molecules. Heparin and HS were degraded with heparinase 
and heparitinase, respectively. Proteins in CM concentrated 
10-fold and CMPEDF were digested first with subtilisin. Pro-
tease-treated CM and CMPEDF were reacted with heparinase 
and heparitinase. The appearance of degradation products 
(∆4-hexuronate) was measured by absorbance at 235 nm 
(Extinction coefficient = 5500). Panels A and B show hepari-
nase activity and panels C and D show heparitinase activity. 
Time course and concentration curves of enzymes using 
their respective substrates are shown in panels A and C. Pan-
els B and D correspond to reactions with CM and CMPEDF.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/1
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HS with binding affinity for PEDF. The estimated concen-
trations of these GAGs in the media may vary with cell
density and conditioning time. However, under the con-
ditions used, they were within the linear range of HS-
PEDF complex formation (EC50 = 40 µg/ml) [14].
The fact that depletion of heparin/HS-like GAGs from the
culturing media results in inhibition of PEDF binding to
cell surface receptors points to functional roles for these
GAGs such as those of positive modulators of PEDF-recep-
tor interactions. In this regard, we observed that depletion
from the Y-79 cell cultures of heparin with heparinase was
lower than those depleted of HS with heparitinase, sug-
gesting that the retinoblastoma-derived HS was more ef-
fective than the retinoblastoma-derived heparin. This
observation can be explained by structural, compositional
and functional differences between heparin and HS
GAGs. GAG-binding proteins can be differentially sensi-
tive to variations in GAG structure [27]. GAGs produced
among different cell types have structural and
Figure 4
Media conditioned by retinoblastoma Y-79 cells 
enhances the 125 I-PEDF binding to cell-surface 
receptors. Binding to human retinoblastoma Y-79 cells (1.5 
× 105 cells/ml) was performed with 0.8 nM 125I-PEDF 
(136,000 cpm/point) in their overnight culturing media (con-
ditioned media) or non-conditioned media (fresh media). 
Free and bound ligand was separated by filtration through 
glass fiber filters under vacuum. Non-specific binding was 
binding in the presence of 125-fold molar excess of unla-
belled PEDF. Specific binding was calculated by subtracting 
the non-specific from the total binding. All experimental 
points are given as the average of triplicates.
Figure 5
Effect of GAG lyases and chlorate on 125 I-PEDF bind-
ing to retinoblastoma Y-79 cells. Human retinoblastoma 
Y-79 cells (5 × 105 cells/ml) were cultured in serum-free 
media at 37°C and treated with GAG lyases or chlorate. 
Binding to the treated cells was performed with 2 nM 125I-
PEDF. Free and bound PEDF were separated by filtration 
through glass-fiber filters under vacuum. Non-specific binding 
was determined from binding reactions in the presence of 
50-fold excess of unlabeled ligand. Specific binding was calcu-
lated by subtracting non-specific binding from total binding. 
Panel A. Cells cultured for 16 h were treated with hyaluroni-
dase, heparinase and heparitinase at 37°C for 120 min. All 
experimental points are given as the average of quadrupli-
cates. Panel B. Cells were cultured with or without 30 mM 
sodium chlorate and 10 mM sodium sulfate at 37°C for 16 h 
before the radioligand was added. The binding reactions 
were at 4°C for 30 min. All experimental points are given as 
the average of triplicates.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/1
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compositional differences and structural changes in GAGs
are known to occur in cells undergoing morphological
differentiation and/or malignant transformations [28–
31]. Thus, in the native retina, or other tissue, modulation
of the PEDF-receptor interactions may depend on the
expression of GAGs, which occur during development
and pathological conditions.
Our data offer interesting possibilities of regulation of the
activity of PEDF. The ratio and amount of production of
heparin and HS by cells bearing PEDF receptors may be an
important mechanism to control the activity of PEDF as is
the modulation of the rate of expression of PEDF recep-
tors. The data obtained so far on the action of PEDF on
different cells may have not considered the presence of
these cofactors in the media. The binding of GAGs to
PEDF that modulate the binding of these factors to its re-
ceptor opens also the possibility that different GAGs may
modulate differently the affinity of PEDF for its receptors,
by increasing or even decreasing it in some cases. Finally,
the fact that the GAG and receptor binding regions are on
opposite regions of the PEDF molecule, suggest the possi-
bility of the existence of PEDF mutants or engineered
variants that, having lost or decreased GAG-binding capa-
bilities, still show high affinity for the PEDF receptor in a
way not dependent upon GAGs content or composition.
These possibilities are discussed under the consideration
that some of them may have important implications if
PEDF, or molecules derived from it, are to be used in the
future as therapeutic agents.
The primary consequence of reducing the heparin/HS and
its sulfation was to minimize a binding site required for
PEDF activity. Although GAGs store PEDF in the
extracellular matrix [14], a more direct mechanism ap-
pears necessary, namely, its participation in the binding of
PEDF to its receptor. In a spatial structure of PEDF, the
heparin/HS binding domain of PEDF maps to the oppo-
site side of the neurotrophic active region [20], allowing
distinct and non-overlapping interactions with heparin/
HS on one side of the protein, and with the neurotrophic
receptor on its opposite side. Our data suggest that the in-
trinsic affinity of the cell surface receptor for PEDF appears
low, whereas the heparin/HS-PEDF complex is recognized
with high affinity. In addition, a direct interaction be-
tween the receptor and GAGs may also be necessary. Al-
though details of the mechanism remain to be revealed, it
is clear that heparin/HS is required for the first step of the
neurotrophic activity of PEDF, namely the encounters
with its receptor at the cell surface. The differentiation and
survival of cells in vivo may be regulated not only by the
expression of PEDF and its receptor but also by the tem-
poral and spatial expression of GAGs.
Methods
Materials
Heparin purified from bovine intestinal mucosa, chon-
droitin sulfates A, B and C, chondroitinase ABC, sodium
chlorate, and Toluidine Blue-O were purchased from Sig-
ma. Subtilisin was from Boehringer Mannheim. Hepariti-
nase (E.C.4.2.2.8) and heparinase (E.C.4.2.2.7) purified
from Flavobacterium heparinum were from ICN Biomedi-
cals, Inc. and alternatively from Seikagaku. Heparan sul-
fate (HS) purified from bovine kidney was from
Seikagaku, hyaluronidase (E.C.4.2.2.1) purified from
Streptomyces hyalurolyticus from ICN Pharmaceuticals,
Coomassie Brilliant Blue from BioRad, and Q-Sepharose
from Pharmacia. Recombinant PEDF was purified from
BHK cells containing an expression vector with human
PEDF cDNA, as previously described [19].
Preparation of conditioned media
Human retinoblastoma Y-79 cells (0.45–5 × 106 cells/ml)
were cultured in defined media (MEM containing 10 mM
HEPES, 1 mM Na-pyruvate, 0.1 mM non-essential amino
acids, 1 mM L-glutamine, 1% penicillin/streptomycin
(LifeTechnologies)) at 37°C for 16–24 h. Media exposed
to these conditions is referred as CM. CM was separated
from cells by centrifugation (1000 × g for 5 min at 4°C)
and concentrated by ultrafiltration using membrane
filters with MWCO = 10,000 (Amicon YM10 filters).
GAGs/polyanions purification was performed as follows:
concentrated CM (15 ml) was dialyzed against buffer Q
(50 mM Tris-HCl, pH 8.0, 0.2 M NaCl, 6 M Urea, 0.5%
CHAPS), filtered through a 0.4 micron membrane and its
soluble components subjected to anion-exchange column
chromatography using Q-Sepharose Fast Flow (1 ml bed
volume). The column was washed with 15-column vol-
umes of buffer Q, the bound material eluted with 1.2 M
NaCl and termed CMa. Alternatively, a DEAE-Sephacel
column was used.
PEDF-affinity column chromatography
To identify components with PEDF-binding affinity, puri-
fied recombinant protein was used to prepare PEDF-affin-
ity resin with 3 M Emphaze™ Biosupport Medium (Pierce
Chemical) [18]. CMa was dialyzed against buffer P (20
mM sodium phosphate pH 7, 150 mM NaCl, 0.5%
CHAPS) and filtrated through 0.4 µm filters. The soluble
dialysate was mixed with PEDF-resin (6 mg PEDF/ml res-
in) at a 2:1 volume-to-volume ratio and incubated at 4°C
with gentle rocking for 16 h. The mixture was packed into
a 10 ml Polyprep chromatography column (Bio-Rad) and
washed with 10-column volumes of buffer P. The bound
material was eluted with 10-column volumes of 3 M Na-
Cl, desalted with 20 mM Tris-HCl pH 8.0, 10% glycerol,
treated for protein depletion, dialyzed against deionized
water, lyophilized and resuspended in deionized water.
The final sample was termed CMPEDF. About 100 µl ofBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/1
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CMPEDF were obtained from 100 ml of CM. Alternatively,
concentrated CM was used as starting material and pro-
tein depletion was omitted.
Radioligand binding assays
PEDF binding to cell-surface receptors was assayed using
biologically active radioligand 125I-PEDF and Y-79 cells
[18] by a widely-used method with a mechanism of
retention of receptors on polyethylenimine-treated glass-
fiber filters based mainly on ionic interactions [32]. Poly-
ethylenimine binds strongly to glass, which is negatively
charged and integral membrane proteins tend to be acidic.
The resultant polycationic polyethylenimine-coated glass
can retain cell membranes due to their negative charges.
Because binding of cell-surface receptors to polyethylen-
imine filters is rather insensitive to ionic strength, the ion-
ic phenomenon is thought to be supplemented by
hydrophobic forces and hydrogen binding [32]. The
method used with Y-79 cells and radiolabeled PEDF has
been described before in detail [18]. Briefly, cells cultured
overnight in serum-deprived medium at 37°C were trans-
ferred to ice/water bath for 10 minutes before the addition
of ligand. The reaction mixtures containing cell suspen-
sions with given radioligand concentrations in untreated
or treated media were incubated at 4°C for 90 min, unless
indicated. The free and bound 125I-PEDF were separated
by filtration through glass-fiber filters and the bound radi-
oactivity was determined in the filters using a β-scintilla-
tion counter (Beckman, model LS 3801). Nonspecific
binding was calculated from reactions with a molar-excess
of unlabeled ligand (≥ 50-fold) over radioligand.
Complex-formation assays
Complex formation between PEDF and CM components
was assayed by a method using ultrafiltration through
membranes of 100,000 MW exclusion limit [14]. Binding
reactions were performed with a given concentration of
125I-PEDF in defined or conditioned media, and incuba-
tions with gentle rotation at 4°C for 2 h. Free and bound
ligand were separated by ultrafiltration through Micro-
con-100 (Amicon). The reaction mixtures were diluted
40-fold with cold 20 mM sodium phosphate pH 6.5, 20
mM NaCl, 10% glycerol and immediately ultrafiltrated,
repeating twice to ensure removal of free ligand from the
complexes. Each Microcon retenate cup was transferred to
scintillation vials, mixed with 5 ml BioSafe II liquid scin-
tillation solution (Research Products International) by ex-
tensive vortexing, and its radioactivity determined using a
β-scintillation counter. Nonspecific binding, calculated
from reactions with an excess of unlabeled ligand (100-
fold) over radioligand, reached about 40% of the total
binding.
Enzymatic digestion treatments
The presence of GAGs was assayed using specific GAG
lyases, i.e., the presence of heparin, HS, and chondroitin
sulfates with heparinase, heparitinase, and chondroitin
ABC respectively. The amount of GAGs was determined
by the amount of ∆4-hexuronate produced after the elim-
inative cleavage of each substrate by the corresponding
GAG lyase. Samples were depleted of proteins by protease
treatment to avoid interference in absorbance readings of
the product. For heparinase and heparitinase reactions,
samples were treated with 5 milliunits of each enzyme in
150 µl of 0.1 M sodium acetate and 1 mM CaCl2, pH 7
and incubations at 37°C for various time periods. The re-
actions were stopped by the addition of 1 ml of 0.06 M
HCl. The soluble material was separated by centrifugation
(3000 × g, 10 min) and assayed for absorbance at 235 nm
to measure the concentration of product ∆4-hexuronate
(Molar extinction coefficient = 5500; [33]). For the chon-
droitinase ABC reactions, each chondroitin sulfates A, B
and C substrate (1 mg each) and concentrated CM, were
incubated with 0.12 units of chondroitinase ABC in 1 ml
of 50 mM Tris-HCl pH 8.0, 60 mM sodium acetate, and
0.02% BSA at 37°C. At various time periods, aliquots of
0.1 ml were removed and mixed with 0.9 ml of 45 mM
KCl pH 1.8 to stop the reaction. Insoluble material was re-
moved by centrifugation (1000 × g, 10 min) and the su-
pernatant assayed for absorbance of ∆4-hexuronate at 232
nm. For protein depletion, CM was mixed with subtilisin
at 0.4 µg/ml in 20 mM Tris-HCl pH 8.0, 10% glycerol and
incubated at 37°C for 16 h. Subtilisin was heat-inactivat-
ed at 75°C for 25 min. The protein concentration after the
reaction was less than 0.1% of the starting material.
To deplete cell cultures of GAGs, Y-79 cells in defined se-
rum-free medium (as above) at a density of 1.25 × 105
cells/ml were cultured in 96-well culture plates (150 µl/
well) and incubated at 37°C in a 5% CO2 environment
for 16 h. Hyaluronidase (>1TRU/µl), heparinase (1 mu/
µl) or heparitinase (1 mu/µl) were each added to various
wells and incubated at 37°C in a 5% CO2 environment
for 1 h.
Chlorate treatment of cell cultures
To prevent sulfation of GAGs in cell cultures, we used a
method previously described [33]. Y-79 cells (1.25 × 105
cells/ml) were cultured in 48-well plates (300 µl/well) in
defined serum-free medium with or without 30 mM sodi-
um chlorate and 10 mM sodium sulfate at 37°C in a 5%
CO2 environment for 24 h.
GAG detection assays
GAGs and proteins resolved by SDS-polyacrylamide gel
electrophoresis in Tricine/SDS buffer, as instructed by
manufacturer (Novex), were detected with specific stains.
For GAG detection, the gels were incubated sequentiallyBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/1
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in 0.2% Toluidine Blue-O in ethanol-water-acetic acid
(50:49:1) for 30 minutes, in ethanol-water-acetic acid
(50:49:1) for 1 h, and in H2O for 16 h. [34]. For protein
detection, the gels were sequentially incubated in 0.5%
Coomassie Brilliant Blue in 50% methanol/10% acetic
acid and in 10% methanol/10% isopropanol. GAG detec-
tion was also performed by the Toluidine Blue-O precipi-
tation and dot-blot method as described previously [34].
Briefly, 200 µl of sample were applied to each well of a 48-
well manifold (Life Technologies) onto a PVDF
membrane without vacuum. Then, 5 µl of 0.2% Toluidine
blue-O were added to each well and vacuum was applied.
The membrane was removed, washed twice with destain-
ing solution (ethanol-water-acetic acid, 50:49:1) for 5
min and air-dried.
Other methods
The protein concentration was determined using BioRad
Protein Assay (BioRad).
Abbreviations
PEDF, pigment epithelium-derived factor; GAG, gly-
cosaminoglycan; HS, heparan sulfate; CM, media condi-
tioned by retinoblastoma cells.
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